Nephrologist expert commentary: The CREDENCE trial (with Andrew Frankel)
Andrew Frankel, Consultant Physician and Nephrologist at Imperial College Healthcare NHS Trust, tells medwireNews about the rationale and key findings of the CREDENCE trial, and discusses the potential benefits of SGLT2 inhibitors beyond type 2 diabetes.
Find more on Medicine Matters diabetes
This content was originally published on Medicine Matters diabetes (https://diabetes.medicinematters.com) on April 17, 2019.
Create your
podcast in
minutes
It is Free